Literature DB >> 20117720

Posterior chamber toric phakic intraocular lens implantation for high myopic astigmatism in eyes with pellucid marginal degeneration.

Kazutaka Kamiya1, Kimiya Shimizu, Fumika Hikita, Mari Komatsu.   

Abstract

UNLABELLED: We report a case in which toric intraocular Collamer lenses (ICLs) effectively corrected the refractive errors of pellucid marginal degeneration (PMD). Preoperatively, in the patient's right eye, the manifest refraction was -10.5 -3.5 x 55, the uncorrected distance visual acuity (UDVA) was 20/1000, and the corrected distance visual acuity (CDVA) was 20/16; in the left eye, the manifest refraction was -11.0 - 6.5 x 130 and the UDVA and CDVA were 20/1000 and 20/20, respectively. After bilateral implantation of a toric ICL, in the right eye, the manifest refraction was +1.50 - 0.75 x 10, the UDVA was 20/16, and the CDVA was 20/12.5; in the left eye, the manifest refraction was +2.5 -3.25 x 125 and the UDVA and CDVA were 20/40 and 20/16, respectively. No sign of progressive disease and no vision-threatening complication were observed during the 6-month follow-up. Toric ICL implantation may be a viable surgical option for the correction of high myopic astigmatism in eyes with PMD. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned. Additional disclosures are found in the footnotes. Copyright 2010 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20117720     DOI: 10.1016/j.jcrs.2009.08.021

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  1 in total

1.  Mini-incision cataract surgery and toric lens implantation for the reduction of high myopic astigmatism in patients with pellucid marginal degeneration.

Authors:  A Balestrazzi; S Baiocchi; A Balestrazzi; G Cartocci; G M Tosi; G Martone; P Michieletto
Journal:  Eye (Lond)       Date:  2015-02-27       Impact factor: 3.775

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.